

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/700,222	11/03/2003	Haeri Roh-Schmidt	3086/1435 (NP 4070)	3084
7590 01/10/2005			EXAMINER	
G. PETER NICHOLS			MCCORMICK EWOLDT, SUSAN BETH	
Brinks Hofer Gilson & Lione NBC Tower, Suite 3600			ART UNIT	PAPER NUMBER
P.O. Box 10395			1654	
Chicago, IL 60610			DATE MAILED: 01/10/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

		T	
	Application No.	Applicant(s)	
	10/700,222	ROH-SCHMIDT ET AL.	
Office Action Summary	Examiner	Art Unit	
	Susan B. McCormick-Ewoldt	1654	
The MAILING DATE of this communication  Period for Reply	on appears on the cover sheet with	the correspondence address	
A SHORTENED STATUTORY PERIOD FOR F THE MAILING DATE OF THIS COMMUNICAT  - Extensions of time may be available under the provisions of 37 ( after SIX (6) MONTHS from the mailing date of this communicat  - If the period for reply specified above is less than thirty (30) days  - If NO period for reply is specified above, the maximum statutory  - Failure to reply within the set or extended period for reply will, by Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	ION.  CFR 1.136(a). In no event, however, may a reply ion.  s, a reply within the statutory minimum of thirty (3) period will apply and will expire SIX (6) MONTHS at the statute, cause the application to become ABANI	be timely filed  0) days will be considered timely.  5 from the mailing date of this communication.  DONED (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on	03 November 2003.		
2a) This action is <b>FINAL</b> . 2b) ∑	This action is non-final.	•	
3) Since this application is in condition for a closed in accordance with the practice ur		-	
Disposition of Claims	• • •		
4)  Claim(s) 1-16 is/are pending in the application 4a) Of the above claim(s) is/are with 5)  Claim(s) is/are allowed.  6)  Claim(s) 1-16 is/are rejected.  7)  Claim(s) is/are objected to.  8)  Claim(s) are subject to restriction	thdrawn from consideration.		
Application Papers			
9) ☐ The specification is objected to by the Exa	aminer.		
10) The drawing(s) filed on is/are: a)			
Applicant may not request that any objection	·	• •	
Replacement drawing sheet(s) including the of the control of the c		•	
Priority under 35 U.S.C. § 119		•	
12) Acknowledgment is made of a claim for for a) All b) Some * c) None of:  1. Certified copies of the priority docu 2. Certified copies of the priority docu 3. Copies of the certified copies of the application from the International E * See the attached detailed Office action for	iments have been received. Iments have been received in Apple priority documents have been received (PCT Rule 17.2(a)).	lication No ceived in this National Stage	
Attachment(s)			
1) Notice of References Cited (PTO-892)	4) 🔲 Interview Sum	mary (PTO-413)	
2) D Notice of Draftsperson's Patent Drawing Review (PTO-94	18) Paper No(s)/M	fail Date	
3) Information Disclosure Statement(s) (PTO-1449 or PTO/S Paper No(s)/Mail Date <u>February 9, 2004</u> . <i>And Appril</i> 1		mal Patent Application (PTO-152)	

Application/Control Number: 10/700,222

Art Unit: 1654

#### **DETAILED ACTION**

#### Claims Pending

Claims 1-16 will be examined on their merits.

#### Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim1-7 and 10-15 are rejected under 35 U.S.C. 102(b) as being anticipated by Vinson et al. (FEBS Letters 433 (1998) 44-46) in light of the Teaflavin website (<a href="http://www.teaflavin.com/TeaFlavin/theaflavins.aspx">http://www.teaflavin.com/TeaFlavin/theaflavins.aspx</a>) in evidence of inherency. Vinson et al. disclose that by consuming black tea decreased the level of cholesterol in hamsters (mammal) by 17% and 27%, respectively (pg. 45, column 1, paragraph 2). Vinson discusses that tea contains theaflavins (pg. 44paragraph spanning columns 1 & 2) but does not specifically teach that the tea contains all of the theaflavins claimed. The TeaFlavin website teaches that black tea naturally contains all of the theaflavins claimed. Thus, the black tea used by Vinson to lower cholesterol would inherently contain all of the theaflavins claimed. Therefore, Vinson properly anticipates the stated claims.

### Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vinson et al.

Application/Control Number: 10/700,222

Art Unit: 1654

Vinson et al. specifically discloses the benefits of drinking black and green tea in mammals and the effects it had on cholesterol as discussed supra. Vinson et al. does not specifically disclose the claimed amounts of theaflavins but as discussed above it is recognized that black tea contains theaflavins. The reference specifically teaches that the theaflavins are and active cholesterol-lowering ingredient. One of ordinary skill in the art would be motivated to modify the amount of theaflavins in the cited reference to best lower cholesterol levels (Vinson et al. page 44, column 1, paragraph). The concentrations of active components are well-known result-effective variables, which would have been routinely optimized by one of ordinary skill in the art.

From the teaching of the reference, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention.

Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the cited references, especially in the absence of evidence to the contrary.

#### Summary

No claim is allowed.

## Future Correspondence

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Susan B. McCormick-Ewoldt whose telephone number is (571) 272-0981. The Examiner can normally be reached Monday through Thursday from 6:00 a.m. to 4:30 p.m.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Bruce Campell, can be reached on (571) 272-0974. The official fax number for the group is (571) 273-8300.

Application/Control Number: 10/700,222

Art Unit: 1654

Page 4

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

sbme

SUSAN D. COE